CTC analysis: an update on technological progress

Batth, Izhar Singh; Mitra, Abhisek; Rood, Sierra; Kopetz, Scott; Menter, David G.; Li, Shulin

doi:10.1016/j.trsl.2019.07.003

Cited by 25 publications

(25 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the years, many technologies have been developed for CTC detection, which have been employed for CTC cluster analysis as well [21,22]. Most of the studies focusing on the clinical significance of CTC clusters in breast cancer have used the CellSearch platform and reported clusters in about 17-20% of patients with metastatic breast cancer, associated with worse prognosis and high CTC burden (five or more CTCs) [14][15][16][17]23].…”

Section: Ctc Cluster Detectionvarious Technologies With Different Advantagesmentioning

confidence: 99%

Better together: circulating tumor cell clustering in metastatic cancer

et al. 2021

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are vital components of liquid biopsies for diagnosis of residual cancer, monitoring of therapy response, and prognosis of recurrence. Scientific dogma focuses on metastasis mediated by single CTCs, but advancement of CTC detection technologies has elucidated multicellular CTC clusters, which are associated with unfavorable clinical outcomes and a 20-to 100-fold greater metastatic potential than single CTCs. While the mechanistic understanding of CTC cluster formation is still in its infancy, multiple cell adhesion molecules and tight junction proteins have been identified that underlie the outperforming attributes of homotypic and heterotypic CTC clusters, such as cell survival, cancer stemness, and immune evasion. Future directions include high-resolution characterization of CTCs at multiomic levels for diagnostic/prognostic evaluations and targeted therapies. Circulating tumor cells form clusters that enhance breast cancer metastasisAlthough metastasis accounts for 90% of solid tumor-related mortality, it currently evades targeted treatments and demands a better understanding. Metastasis is a multistep process during which cancer cells spread from the primary tumor site to distant organs, starting with the primary tumor formation, where tumor cells gradually expand and locally invade the surrounding stroma and tissues, including the blood and lymphatic vessels. At this point, the intravasated tumor cells, now called 'circulating tumor cells' (CTCs) and a vital component of liquid biopsy [1,2], develop adaptive mechanisms that favor their survival in the harsh microenvironment of the circulatory system. CTCs may disseminate to distant parts of the body before they finally extravasate or get trapped within the capillaries in certain organs, form metastatic niches, and regenerate secondary tumors [3][4][5].The presence of CTCs in the blood of patients with cancer was first detected in 1869 by Thomas Ashworth [6], but, because of advances in technology, CTCs have only recently attracted great attention for their key role in tumor metastasis [6,7]. Many studies have shown that CTCs may be used to predict disease progression and prognosis in patients with metastatic cancer [4]. In metastatic cancers such as breast cancer, the currently accepted level of CTCs that correlates with worse overall survival and progression-free survival is five or more CTCs in 7.5 mL of blood [8]. CTC enumeration can be used to better stratify patients with stage IV breast cancer as stage IV aggressive, with more than five CTCs, and stage IV indolent, with fewer than five CTCs [8]. Stage IV indolent disease is associated with significantly longer overall survival, regardless of disease subtype and prior treatment [8]. The presence of CTCs in early breast cancer was also demonstrated to have prognostic impact [9,10]. Thus, CTC analysis in patients with cancer is a minimally invasive, clinically informative method of predicting disease stage and survival that is not dependent on cancer subtype or previous trea...

show abstract

Section: Ctc Cluster Detectionvarious Technologies With Different Advantagesmentioning

confidence: 99%

Better together: circulating tumor cell clustering in metastatic cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The process by which tumor cells invade the body remains unclear and may involve the active invasion of cells via epithelial-to-mesenchymal transition (16) and passively shed individual cells or clusters of tumor cells from impaired tumor blood vessels (17,18). The presence of CTCs in the peripheral blood is considered to be the key factor of tumor metastasis (19). A number of studies have evaluated the clinical application value of CTCs for metastatic breast (20,21), prostate (22), colon (23) and lung (24,25) cancer.…”

Section: Discussionmentioning

confidence: 99%

“…The technology detects the biomarkers on the cell surface to identify the CTCs (26,27). The downregulation or absence of epithelial markers should have an effect on detecting CTCs (19). Thus, the discovery of new tumor markers may help identify CTCs in the peripheral blood of patients with malignant tumors.…”

Section: Discussionmentioning

confidence: 99%

MAGE‑A genes as predictors of the outcome of laryngeal squamous cell carcinoma

Liu

Zhao

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant tumors in the head and neck area. Melanoma-associated antigens A (MAGE-A) are strictly tumor-specific and are expressed in several types of tumors. To date, no studies have reported the potential of MAGE-A genes as markers for circulating tumor cells (CTCs) in patients with LSCC. The present study aimed to evaluate the expression and the possible prognostic significance of MAGE-A in the peripheral blood of patients with LSCC. In the present study, the expression of MAGE-A genes was determined by multiplex semi-nested PCR and restriction endonuclease treatment of the peripheral blood of patients with LSCC. The association between MAGE-A gene expression and clinicopathological parameters and prognosis was evaluated. The results demonstrated that the expression of MAGE-A was associated with the predictors that indicate poor prognosis. The expression levels of MAGE-A and each individual MAGE-A gene were also associated with a shorter overall survival time of patients with LSCC. In conclusion, the results of the present study suggested that the expression of MAGE-A genes may be a potential prognostic marker for patients with LSCC.

show abstract

“…CTC carries the genetic and phenotypic information of tumor tissues, which can guide patients with CRC to take drugs and detect resistance. 5,6 At present, the detection and research of CTC have been verified in colorectal cancer, non-small cell lung cancer, breast cancer and so on. [7][8][9] KRAS gene (Kirsten rat sarcoma viral oncogene) participates in the regulation of signal pathways such as MAPK, PI3K and Ral-GEFs.…”

Section: Introductionmentioning

confidence: 99%

<p>Construction and Characterization of KRAS Immune Lipid Magnetic Balls for Colorectal Cancer Circulating Tumor Cells</p>

Feng

Wang

Yang

et al. 2020

CMAR

View full text Add to dashboard Cite

The purpose of this study was to prepare and characterize a lipid magnetic ball modified with KRAS antibodies on the surface and to isolate circulating tumor cells of colorectal cancer with KRAS mutations. Methods: The microemulsion method was used to form lipid bilayers to encapsulate Fe3O4 nanoparticles with superparamagnetism to form lipid magnetic balls, and KRAS antibodies were formed on the surface to form KRAS immune lipid magnetic balls. Results: Compared with traditional EpCAM antibody-modified lipid magnetic balls, it can effectively improve the capture ability of colorectal cancer circulating tumor cells with KRAS mutation, the capture rate reaches 92.9%, and the capture results are consistent with clinical diagnosis and pathology. Conclusion: Our results showed that KRAS antibody-modified lipid magnetic balls can be used in the diagnosis and treatment of KRAS colorectal cancer.

show abstract

CTC analysis: an update on technological progress

Cited by 25 publications

References 91 publications

Better together: circulating tumor cell clustering in metastatic cancer

Better together: circulating tumor cell clustering in metastatic cancer

MAGE‑A genes as predictors of the outcome of laryngeal squamous cell carcinoma

<p>Construction and Characterization of KRAS Immune Lipid Magnetic Balls for Colorectal Cancer Circulating Tumor Cells</p>

Contact Info

Product

Resources

About